The Experts below are selected from a list of 57 Experts worldwide ranked by ideXlab platform
Oliver Dudeck - One of the best experts on this subject based on the ideXlab platform.
-
Advantages and Disadvantages of the Amplatzer Vascular Plug IV in Visceral Embolization: Report of 50 Placements
CardioVascular and Interventional Radiology, 2011Co-Authors: Maciej Pech, Ricarda Seidensticker, Adam Zapasnik, Konrad Mohnike, Jens Ricke, Gero Wieners, Max Seidensticker, Oliver DudeckAbstract:Purpose We describe our initial clinical experience in Artificial Embolization with the Amplatzer Vascular Plug IV (VP IV), a further development of the Vascular Plug family already in routine use. Methods Results from 50 Embolization procedures conducted with the VP IV in 44 patients are summarized. Results All 50 Embolizations were successful, although two required the technique to be modified because of problems with jamming of the screw thread and thus with disconnection of the plug. This was associated with large branching angles. Conclusions With experience, the VP IV can be used safely and effectively, and it expands the spectrum of possible Embolizations in interventional radiology. Its greatest disadvantage is its relatively poor positional controllability.
-
Advantages and Disadvantages of the Amplatzer Vascular Plug IV in Visceral Embolization: Report of 50 Placements
CardioVascular and Interventional Radiology, 2011Co-Authors: Maciej Pech, Ricarda Seidensticker, Adam Zapasnik, Konrad Mohnike, Jens Ricke, Gero Wieners, Max Seidensticker, Oliver DudeckAbstract:Purpose We describe our initial clinical experience in Artificial Embolization with the Amplatzer Vascular Plug IV (VP IV), a further development of the Vascular Plug family already in routine use.
Irwin J. Griffith - One of the best experts on this subject based on the ideXlab platform.
-
A Preclinical Study of the Safety and Efficacy of Occlusin™ 500 Artificial Embolization Device in Sheep
CardioVascular and Interventional Radiology, 2012Co-Authors: Richard J. Owen, Patrick N. Nation, Robert Polakowski, Jennifer A. Biliske, Paul B. Tiege, Irwin J. GriffithAbstract:Introduction This study evaluated the safety, effectiveness, and biodegradation of a new embolic agent, Occlusin™ 503 Artificial Embolization Device (OCL 503). The agent consists of biodegradable poly-lactic-co-glycolic acid microspheres (150–212 μm) coated with type I bovine collagen and was compared with Embosphere^® Microspheres (300–500 μm) in this controlled study of uterine artery Embolization (UAE) in sheep. Methods Unilateral UAE was performed in 32 adult ewes randomly assigned. Vessels were embolized to effective stasis. The cohort was divided into four groups, which were sacrificed at 1, 3, 6, and 12 months. Results Both agents were 100% effective in achieving stasis. At 6 months, all OCL 503-treated arteries were occluded, the microspheres degraded with time, and at 12 months all four animals examined demonstrated recanalization. OCL 503 was found in the untreated uterine artery in one animal with no other evidence of non target Embolization. In the Embosphere-treated group, all vessels remained occluded and microspheres were detected in the contralateral uterine artery in 6 of 15 examined vessels and in 10 vaginal, 2 ovarian, and 1 vesical artery. No procedural-related complications were seen in either group. Conclusions OCL 503 is as effective an embolic agent as Embosphere^® Microspheres when embolizing ovine uterine arteries and resorbs with time, allowing recanalization of the treated arteries. No device-related issues or adverse events were observed.
-
A preclinical study of the safety and efficacy of Occlusin™ 500 Artificial Embolization Device in sheep.
Cardiovascular and interventional radiology, 2011Co-Authors: Richard J. Owen, Patrick N. Nation, Robert Polakowski, Jennifer A. Biliske, Paul B. Tiege, Irwin J. GriffithAbstract:Introduction This study evaluated the safety, effectiveness, and biodegradation of a new embolic agent, Occlusin™ 503 Artificial Embolization Device (OCL 503). The agent consists of biodegradable poly-lactic-co-glycolic acid microspheres (150–212 μm) coated with type I bovine collagen and was compared with Embosphere® Microspheres (300–500 μm) in this controlled study of uterine artery Embolization (UAE) in sheep.
Maciej Pech - One of the best experts on this subject based on the ideXlab platform.
-
Advantages and Disadvantages of the Amplatzer Vascular Plug IV in Visceral Embolization: Report of 50 Placements
CardioVascular and Interventional Radiology, 2011Co-Authors: Maciej Pech, Ricarda Seidensticker, Adam Zapasnik, Konrad Mohnike, Jens Ricke, Gero Wieners, Max Seidensticker, Oliver DudeckAbstract:Purpose We describe our initial clinical experience in Artificial Embolization with the Amplatzer Vascular Plug IV (VP IV), a further development of the Vascular Plug family already in routine use. Methods Results from 50 Embolization procedures conducted with the VP IV in 44 patients are summarized. Results All 50 Embolizations were successful, although two required the technique to be modified because of problems with jamming of the screw thread and thus with disconnection of the plug. This was associated with large branching angles. Conclusions With experience, the VP IV can be used safely and effectively, and it expands the spectrum of possible Embolizations in interventional radiology. Its greatest disadvantage is its relatively poor positional controllability.
-
Advantages and Disadvantages of the Amplatzer Vascular Plug IV in Visceral Embolization: Report of 50 Placements
CardioVascular and Interventional Radiology, 2011Co-Authors: Maciej Pech, Ricarda Seidensticker, Adam Zapasnik, Konrad Mohnike, Jens Ricke, Gero Wieners, Max Seidensticker, Oliver DudeckAbstract:Purpose We describe our initial clinical experience in Artificial Embolization with the Amplatzer Vascular Plug IV (VP IV), a further development of the Vascular Plug family already in routine use.
Richard J. Owen - One of the best experts on this subject based on the ideXlab platform.
-
A Preclinical Study of the Safety and Efficacy of Occlusin™ 500 Artificial Embolization Device in Sheep
CardioVascular and Interventional Radiology, 2012Co-Authors: Richard J. Owen, Patrick N. Nation, Robert Polakowski, Jennifer A. Biliske, Paul B. Tiege, Irwin J. GriffithAbstract:Introduction This study evaluated the safety, effectiveness, and biodegradation of a new embolic agent, Occlusin™ 503 Artificial Embolization Device (OCL 503). The agent consists of biodegradable poly-lactic-co-glycolic acid microspheres (150–212 μm) coated with type I bovine collagen and was compared with Embosphere^® Microspheres (300–500 μm) in this controlled study of uterine artery Embolization (UAE) in sheep. Methods Unilateral UAE was performed in 32 adult ewes randomly assigned. Vessels were embolized to effective stasis. The cohort was divided into four groups, which were sacrificed at 1, 3, 6, and 12 months. Results Both agents were 100% effective in achieving stasis. At 6 months, all OCL 503-treated arteries were occluded, the microspheres degraded with time, and at 12 months all four animals examined demonstrated recanalization. OCL 503 was found in the untreated uterine artery in one animal with no other evidence of non target Embolization. In the Embosphere-treated group, all vessels remained occluded and microspheres were detected in the contralateral uterine artery in 6 of 15 examined vessels and in 10 vaginal, 2 ovarian, and 1 vesical artery. No procedural-related complications were seen in either group. Conclusions OCL 503 is as effective an embolic agent as Embosphere^® Microspheres when embolizing ovine uterine arteries and resorbs with time, allowing recanalization of the treated arteries. No device-related issues or adverse events were observed.
-
A preclinical study of the safety and efficacy of Occlusin™ 500 Artificial Embolization Device in sheep.
Cardiovascular and interventional radiology, 2011Co-Authors: Richard J. Owen, Patrick N. Nation, Robert Polakowski, Jennifer A. Biliske, Paul B. Tiege, Irwin J. GriffithAbstract:Introduction This study evaluated the safety, effectiveness, and biodegradation of a new embolic agent, Occlusin™ 503 Artificial Embolization Device (OCL 503). The agent consists of biodegradable poly-lactic-co-glycolic acid microspheres (150–212 μm) coated with type I bovine collagen and was compared with Embosphere® Microspheres (300–500 μm) in this controlled study of uterine artery Embolization (UAE) in sheep.
Ricarda Seidensticker - One of the best experts on this subject based on the ideXlab platform.
-
Advantages and Disadvantages of the Amplatzer Vascular Plug IV in Visceral Embolization: Report of 50 Placements
CardioVascular and Interventional Radiology, 2011Co-Authors: Maciej Pech, Ricarda Seidensticker, Adam Zapasnik, Konrad Mohnike, Jens Ricke, Gero Wieners, Max Seidensticker, Oliver DudeckAbstract:Purpose We describe our initial clinical experience in Artificial Embolization with the Amplatzer Vascular Plug IV (VP IV), a further development of the Vascular Plug family already in routine use. Methods Results from 50 Embolization procedures conducted with the VP IV in 44 patients are summarized. Results All 50 Embolizations were successful, although two required the technique to be modified because of problems with jamming of the screw thread and thus with disconnection of the plug. This was associated with large branching angles. Conclusions With experience, the VP IV can be used safely and effectively, and it expands the spectrum of possible Embolizations in interventional radiology. Its greatest disadvantage is its relatively poor positional controllability.
-
Advantages and Disadvantages of the Amplatzer Vascular Plug IV in Visceral Embolization: Report of 50 Placements
CardioVascular and Interventional Radiology, 2011Co-Authors: Maciej Pech, Ricarda Seidensticker, Adam Zapasnik, Konrad Mohnike, Jens Ricke, Gero Wieners, Max Seidensticker, Oliver DudeckAbstract:Purpose We describe our initial clinical experience in Artificial Embolization with the Amplatzer Vascular Plug IV (VP IV), a further development of the Vascular Plug family already in routine use.
